Hyalose, LLC is a biotechnology company focused on the commercialization of unique recombinant technologies for producing Hyaluronic Acid (HA), an important biomolecule for many healthcare and cosmetic applications.
With a strong intellectual property portfolio and scientific expertise, Hyalose meets today’s market demands for highly controlled HA production.
Hyalose is a portfolio company of leading life sciences technology management firm Emergent Technologies, Inc. with business operations based in Austin, TX.
In 2019, Hyalose selected Echelon Biosciences, Inc. of Salt Lake City, Utah, to serve as the new, sole distributor of its Select-HA products. See press release here.
Hyaluronan (hyaluronic acid, HA) is a type of sugar polymer called a polysaccharide (other common polysaccharides include cellulose from wood, or starch from food). HA is a member of the glycosaminoglycan family. The chemical structure of HA is a chain of two different simple sugars (N-acetylglucosamine and glucuronic acid) repeated over and over. In nature, the length of the polymer chains ranges from hundreds to thousand of sugars units and can exist in as short or long chains.
In the agarose gel (left lane), Select-HA products are tight bands, much as the DNA ladder in the middle lane. The sizes (masses) of the Select-HA products have been determined by GPC-MALLS. Other commercial HA prodcuts have much greater size heterogeneity and run as a smear (right lane) averaging 587 kDa.Hyalose is seeking collaborators to implement this patented technology to produce products where the specific molecular weight of the HA matters.
In May 2002, Hyalose licensed its recombinant Bulk HA technology to Novozymes Biopolymer A/S, a wholly owned subsidiary of Novozymes A/S (NYSE: NVZMF). Based on this unique expression technology Novozymes Biopharma today manufactures and markets a better defined, controlled and safe sodium hyaluronate under the brand name Hyasis.
Please see the link and brochure below for more information on Hyasis®.
Link to website
Link to brochure
Hyalose has formed a "Tool Kit" of methods for the innovative synthesis of designer polysaccharide products utilizing recombinant enzymes. The enabling technology is the use of soluble enzymes to create unique new hybrid polymers and polysaccharide conjugates.
Hyalose is seeking collaborators to implement this patented technology to produce products where the specific molecular weight and the composition of hyaluronic acid and/or hybrids of GAGs matter.
- HA of a defined polymer length and content and
- HA from a Generally Regarded As Safe (GRAS) bacterial source.
Hyalose Frequently Asked Questions
Product ListProduct FAQs
For all other inquiries, please contact us at firstname.lastname@example.org.
Weigel, P.H. and DeAngelis P.L. (2007) Hyaluronan Synthases: A Decade-plus of Novel Glycosyltransferases. J. Biol. Chem., 282: 36777-36781.
Jing, W., Haller, M., Almond, A. and DeAngelis, P.L. (2006) Defined megadalton hyaluronan polymer standards. Anal Biochem.15;355(2):183-8.
Widner, W., Behr, R., Von Dollen, S., Tang, M., Heu, T., Sloma, A., Sternberg, D., DeAngelis, P.L., Weigel, P.H. and Brown, S. (2005) Hyaluronic acid production in Bacillus subtilis. Applied and Environmental Microbiol. 71:3747-3752.
Jing, W and DeAngelis, P.L. (2004) Synchronized chemoenzymatic synthesis of monodisperse hyaluronan polymers. J. Biol. Chem., 279(40), 42345-42349.
Product Orders:675 Arapeen Dr. Ste. 302
Salt Lake City, UT 84108
Phone: (801) 588-0455
Fax: (801) 588-0497
Business Operations:Emergent Technologies, Inc.
7500 Rialto Blvd., Building 2, Suite 260
Austin, Texas 78735
Phone: (512) 263-3232, ext. 8
Fax: (512) 263-3236